Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2022-03-17 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Akili Adds Gaming Vet as Chief Product Officer
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from PureTech Health PLC, dated March 17, 2022. The primary content is an announcement regarding its Founded Entity, Akili Interactive, appointing a new Chief Product Officer (Jon David). This type of announcement, detailing executive changes within the company or its subsidiaries, directly maps to the Board/Management Information category. Although it mentions an ongoing SPAC merger and references SEC filings (Form S-4, proxy statement/prospectus), the core purpose of this specific release is the management appointment, not the filing of the merger documents themselves. Therefore, MANG is the most appropriate classification.
2022-03-17 English
Gelesis: Record-Breaking Plenity Prescriptions
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from PureTech Health PLC, dated March 16, 2022. The content primarily relays preliminary launch results for a product (Plenity) made by its Founded Entity, Gelesis. It includes key performance indicators (prescriptions, revenue projections) and forward-looking statements. This format—a brief announcement of operational/commercial updates released via a regulatory wire service (RNS Number: 8964E)—is characteristic of a general regulatory filing or news release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is a formal announcement disseminated through the RNS system and contains operational updates, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement category.
2022-03-16 English
Akili Named to World's Most Innovative Companies
Regulatory Filings Classification · 100% confidence The document is dated March 8, 2022, and is issued via RNS (RNS Number : 0434E), which suggests a regulatory announcement. The content primarily reports on a press release from PureTech Health's founded entity, Akili, announcing that Akili was named to Fast Company's 'World's 50 Most Innovative Companies for 2022' list. This is a general corporate announcement regarding an award/recognition, not a mandatory financial filing like a 10-K, an earnings release (ER), or a specific capital event. Since it is a general, non-financial, non-statutory announcement distributed through the RNS system, the most appropriate classification is the general regulatory announcement fallback category, RNS.
2022-03-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number' and contains standard regulatory notification tables, specifically 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds). The definition for Major Shareholding Notification is 'MRQ: Notification of changes in significant share ownership levels (crossing thresholds)'. Although it is distributed via RNS, the content is specific to a major holding change, making MRQ the most accurate classification over the general RNS fallback.
2022-02-18 English
Akili Data: Enhanced Brain Activity in Kids w/ADHD
Legal Proceedings Report Classification · 99% confidence The document is an RNS (Regulatory News Service) announcement from PureTech Health PLC, dated February 17, 2022. The core content announces that its Founded Entity, Akili Interactive Labs, has had clinical study results published in the medical journal PLOS ONE regarding its digital therapeutic, EndeavorRx. While it discusses scientific data and includes a full reprint of Akili's announcement, the primary function of this document, as filed via RNS, is to disseminate this news to the market. It is not a comprehensive financial report (like 10-K or IR), nor is it solely a proxy statement (DEF 14A) or a management discussion (MDA). Since it is a general, time-sensitive regulatory announcement of an external event (publication of study results) that is material to the company's prospects, and it doesn't fit neatly into the other specific categories (like DIV, CAP, or DIRS), the most appropriate classification is the general regulatory filing category, RNS. The document length is substantial (over 22k characters), so it is not a simple RPA.
2022-02-17 English
PRTC's Akili Files Registration Statement on S-4
Regulatory Filings Classification · 99% confidence The document is an RNS announcement from PureTech Health PLC regarding its Founded Entity, Akili Interactive. The core subject is Akili's announcement that Social Capital Suvretta Holdings Corp. I (SCS) has filed a Registration Statement on Form S-4 with the SEC in connection with a proposed business combination (merger/acquisition). This type of announcement, detailing the filing of a key regulatory document (S-4) related to a major corporate transaction (business combination/SPAC merger), fits best under the category of M&A Activity (TAR). Although it mentions SEC filings, the primary focus is the transaction itself, not a general regulatory update (RNS) or a proxy solicitation (PSI) for a shareholder vote on the merger yet. Since it explicitly discusses the proposed business combination and the S-4 filing related to it, TAR is the most appropriate classification.
2022-02-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.